Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.7325 USD | -3.75% | -9.58% | +28.51% |
07:05pm | Oppenheimer Adjusts Price Target on Viracta Therapeutics to $11 From $13, Maintains Outperform Rating | MT |
May. 14 | Viracta Therapeutics Appoints Michael Faerm CFO | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+28.51% | 29.89M | |
+64.83% | 62.59B | |
-2.04% | 41.18B | |
+44.76% | 40.29B | |
-8.93% | 27.9B | |
+12.98% | 26.21B | |
-21.88% | 19.09B | |
+3.97% | 13.08B | |
+25.72% | 12.26B | |
+27.16% | 12.05B |
- Stock Market
- Equities
- VIRX Stock
- News Viracta Therapeutics, Inc.
- Transcript : Viracta Therapeutics, Inc. - Special Call